Drug Profile
Research programme: rotavirus inhibitors - Takeda
Alternative Names: VP-1147Latest Information Update: 15 Jan 2019
Price :
$50
*
At a glance
- Originator ViroPharma
- Class Small molecules
- Mechanism of Action Virus replication inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Rotavirus infections
Most Recent Events
- 08 Jan 2019 Shire has been acquired and merged into Takeda
- 01 Jun 2004 Preclinical trials in Rotavirus infections in USA (unspecified route)